Galectin Therapeutics (GALT) Net Cash Flow Growth (3y) (2013 - 2026)
Galectin Therapeutics (GALT) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-13.44% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Galectin Therapeutics |
185.83 Mn |
171.73 Mn |
- |
-65.72% |
| Date | Value |
|---|
| Mar 31, 2026 |
-65.72% |
| Dec 31, 2025 |
30.51% |
| Sep 30, 2025 |
35.85% |
| Jun 30, 2025 |
41.84% |
| Mar 31, 2025 |
1.44% |
| Dec 31, 2024 |
-80.87% |
| Sep 30, 2024 |
-34.22% |
| Jun 30, 2024 |
-42.36% |
| Mar 31, 2024 |
30.96% |
| Dec 31, 2023 |
43.78% |
| Sep 30, 2023 |
31.84% |
| Jun 30, 2023 |
27.35% |
| Mar 31, 2023 |
42.41% |
| Dec 31, 2022 |
43.68% |
| Sep 30, 2022 |
-69.77% |
| Jun 30, 2022 |
-29.36% |
| Mar 31, 2022 |
-84.48% |
| Dec 31, 2021 |
53.53% |
| Sep 30, 2021 |
151.23% |
| Jun 30, 2021 |
18.53% |
